Processa Pharmaceuticals, Inc.
PCSA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PCSA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapies and two non-oncology drugs, utilizing a proprietary Regulatory Science Approach to improve the safety-efficacy profile of existing drugs. The company has incurred losses since inception, has no approved products or product revenue, and faces substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Processa Pharmaceuticals, Inc..
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapies and two non-oncology drugs, utilizing a proprietary Regulatory Science Approach to improve the safety-efficacy profile of existing drugs. The company has incurred losses since inception, has no approved products or product revenue, and faces substantial doubt about its ability to continue as a going concern.
- Processa is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapies (NGC-Cap and NGC-Iri) and two non-oncology drugs (PCS12852 and PCS499) [sec_mda · as of 2026-05-07].
- The company has incurred losses since inception, with an accumulated deficit of $107.4 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company reported cash and equivalents of $0.2 million, net income of -$3.3 million, and shareholders' equity of $5.6 million [sec].
- The company has not generated any product revenue and does not expect to do so in the near future, as none of its drug candidates have been approved for sale [sec_mda · as of 2026-08-14].
- The company's ability to continue as a going concern is in substantial doubt, and it will need to raise additional capital to fund its planned operations [sec_mda · as of 2026-08-14].
What works
- The company's pipeline leverages a proprietary Regulatory Science Approach, which it believes will increase the likelihood of regulatory approval for its Next Generation Cancer therapies [sec_mda · as of 2026-05-07].
- Since the underlying active metabolites of the company's drugs are already commonly used in cancer therapy, the company believes that successful clinical trials showing a better safety-efficacy profile could lead to rapid and broad commercial adoption [sec_mda · as of 2026-05-07].
What to weigh
- The company has incurred losses since inception, with an accumulated deficit of $107.4 million as of June 30, 2026, and no product revenue [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company had only $0.2 million in cash and equivalents, and its ability to continue as a going concern is in substantial doubt [sec_mda · as of 2026-08-14].
- The company will need to raise additional capital to fund its planned operations, and absent additional funding, its current cash will not be sufficient for one year [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $107.4 million as of June 30, 2026.
“have an accumulated deficit of $107.4 million at June 30, 2026.”
SEC MD&A · August 14, 2026
The company has no approved products and no product revenue.
“To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue”
SEC MD&A · August 14, 2026
The company's pipeline includes NGC-Cap and NGC-Iri (PCS6422 and PCS11T) and two non-oncology drugs.
“Our oncology pipeline currently consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499).”
SEC MD&A · May 7, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; cash of $0.2M as of June 30, 2026, insufficient for 12 months [sec_mda · as of 2026-08-14].
- No approved products or revenue — None of the drug candidates have been approved for sale, and the company has not generated any product revenue [sec_mda · as of 2026-08-14].
- Need for additional capital — The company will need to raise additional capital to fund its planned operations, with no assurance of securing funding [sec_mda · as of 2026-08-14].
- Clinical trial risks — The company's future depends on successful clinical trials, which may be delayed or more costly than expected [sec_mda · as of 2026-03-18].
What to watch
- Ability to raise additional capital to fund operations and clinical trials [sec_mda · as of 2026-08-14].
- Progress and results of clinical trials for NGC-Cap and NGC-Iri [sec_mda · as of 2026-05-07].
- Any updates on the company's ability to maintain its Nasdaq listing [sec_mda · as of 2026-08-14].
- Regulatory developments or partnerships that could provide funding or strategic alternatives [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Processa Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Processa Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.1 months
OCF -$2M · Net income -$3M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
41 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$333K
| Holder | Shares | Value |
|---|---|---|
| connective capital management, llc | 70,736 | $179K |
| vanguard capital management llc | 25,458 | $64K |
| geode capital management, llc | 24,908 | $63K |
| vanguard fiduciary trust co | 10,857 | $27K |
| citigroup inc | 14 | $35 |
| jones financial companies lllp | 7 | $17 |
| wells fargo & company/mn | 6 | $15 |
Short Interest
as of May 22, 2026- % of float
- 5.7%
- Days to cover
- 1.8
- Shares short
- 135,440
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PCSA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Processa Pharmaceuticals, Inc.?
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapies and two non-oncology drugs, utilizing a proprietary Regulatory Science Approach to improve the safety-efficacy profile of existing drugs. The company has incurred losses since inception, has no approved products or product revenue, and faces substantial doubt about its ability to continue as a going concern.
Who is the CEO of Processa Pharmaceuticals, Inc.?
Mr. George K. Ng Esq., J.D. is the chief executive officer of Processa Pharmaceuticals, Inc. (PCSA).
Where is Processa Pharmaceuticals, Inc. headquartered?
Processa Pharmaceuticals, Inc. (PCSA) is headquartered in Vero Beach, FL, United States.
What therapeutic areas does Processa Pharmaceuticals, Inc. focus on?
Processa Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.